Stocks to Watch Tomorrow 01/24

Oil rose more than $2 barrel today after getting raped for some time. Tomorrow oil inventories are due at 10:30AM ET. If oil continues to rally it could weigh on stocks.

Yahoo! Inc. (Nasdaq: YHOO) reported after the close and showed they continue to perform like a dead fish compared to Google (Nasdaq: GOOG). Stock up 4% after-hours. The company is talking up their new search platform Panama again on the CC. Where are the resuls already!

Advanced Micro Devices Inc. (NYSE: AMD) reported a dismal quarter. Margins were way below expectations. Looks like Intel and AMD are price cutting each other to death. Down 4.6% AH.

Earnings to watch tomorrow include: McDonald's (NYSE: MCD), SAP AG (NYSE: SAP) (already warned), eBay (Nasdaq: EBAY) and Qualcomm (Nasdaq: QCOM)

Today's pump-it-up-pump-it-up micro cap stock was Optionable Inc. (OTCBB: OPBL). The company had a nice piece of news out which drove the action ---- Mega commodity exchange NYMEX Holdings (NYSE: NMX) is buying 19% of the company. Optionable provides natural gas and other energy derivatives brokerage services.

Stocks to Watch Tomorrow 12/28

Jolly Old Saint Nick kept the presents coming today. The Dow hit a new all-time high over 12,500!

The has-news-will-maniuplate micro cap bull market continued, making us a little cautious. When investors start playing into the greater fool game it is usually a sign of a short-term top. Sento Corp. (Nasdaq: SNTO) jumped 69% today ahead of results, Infosonics Corp. (Nasdaq: IFON) jumpted 44% today after partnering with LG. Nucryst Pharmaceuticals (Nasdaq: NCST) (+30%) and OraLabs Holding (Nasdaq: OLAB) (+37%) both jumped for no good reason. Another one we were watching, ZI Corp. (Nasdaq: ZICA), finally started seeing profit taking after its two-day meteoric rise.

Threshold Pharmaceuticals (Nasdaq: THLD) is moving 20% higher in after-hours action after announceing Phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer. The company said they were "pleased with these encouraging top-line results" While investors don't seem to care, we did notice a note on saftey of the combo in the middle of the press release that could throw a wrench in things. The company said, "Preliminary analysis of the safety data in this Phase 2 glufosfamide and gemcitabine combination trial suggests the incidence of treatment-related nephrotoxicity may be slightly higher than what was observed in previous experience with either of these agents used individually."

See that snap-back in Apple (Nasdaq: AAPL) today? Down nearly $5 early then closed in the green! I guess the big boys were making trades from the slopes after calls on their batphones from the rooks manning the desks. How about GOOG (Nasdaq: GOOG)? - plus $10.50! What up with Citigroup (NYSE: C)? - new 52-week high! Gotta love it!